ARTICLE | Company News
MediciNova, NIH neurology news
October 13, 2014 7:00 AM UTC
MediciNova said NIH's National Institute on Drug Abuse (NIDA) awarded a grant to continue funding a Phase IIa trial of ibudilast ( MN-166) to treat prescription opioids or heroin dependence. The grant is worth over $2.7 million over the next nine months, with a potential award of over $11 million for the next four years. Columbia University and New York State Psychiatric Institute are conducting the trial. ...